Actelion flags looming pivotal data for Tracleer successor; BIO calls on FDA to hire a chief innovation officer;

 @FierceBiotech: Gilead wows analysts as 7977 combos quell hepatitis C in most patients. Article | Follow @FierceBiotech

 @JohnCFierce: I've begun to put more thought into this year's Fierce 15. Not a bad time to start emailing me with suggestions. | Follow @JohnCFierce

 @RyanMFierce: Medivir's stock trading down after new TMC435 data in hepatitis C. In study, up to 80% cured. Disappointing? Article | Follow @RyanMFierce

> Switzerland's Actelion ($ATLN) says it's just weeks away from delivering pivotal data for macitentan, it's crucial follow-on program for Tracleer. Faced with losing patent protection in 2015 on a product that delivers 90% of its sales revenue, success here is vital to the company's future. Story

> BIO chief Jim Greenwood believes the FDA needs to hire a chief innovation officer to help supervise the agency's approach to drug rejections and innovation. Story

> Israel's Prolor says it gained positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. Release

Pharma News

 @FiercePharma: Baxter beats Wall Street projections but gets FDA questions on new treatment. Article | Follow @FiercePharma

> Pfizer, Amgen dissolving Enbrel partnership. Story

Medical Devices News

@FierceMedDev: Interesting: Researchers Discover Non-Surgical Test for Brain Cancer | Release | Follow @FierceMedDev

> Top 10 Medical Device R&D Budgets. Special Report

> Boston Sci sees earnings jump as sales slip . Story

> J&J gains EU nod for $21.3B Synthes deal. News

CRO News

> INC Research and Astellas expand alliance. Article

> Unsecured creditors get more time to bid on Cetero. News

> Moody's eyes investor backlash for InVentiv after CRO acquisitions. More

> Australia's vivoPharm grabs RMIT University drug discovery tech. Story

> Children's tastes overlooked in clinical trials. Item

Vaccine News

> Scancell's DNA melanoma vaccine poised for Phase II. Article

> Passive vaccine could treat cocaine overdose. News

> Personalized brain cancer vaccine improves survival. Story

> Study: Dengue virus research needs to focus on people, not mice. More

> DNA vaccine for prostate cancer moves into Phase III. Item

Pharma Manufacturing

> Baxter to erect $1B plasma plant. Story

> CSL recalling product tainted with ethylene glycol. Article

> U.S. Marshals seize ultrasound gel containing dangerous levels of bacteria. News

> J&J plant overhaul turning into 4-year project. More

And Finally… Researchers at Sweden's Lund University say that a connection between two proteins controls cell division and the possibilities for tumor development. Release

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.